Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Knockout T Cells in Muscle-invasive Bladder Cancer
NCT02863913Phase 1Withdrawn
- Sponsor
- Peking University
- Start
- Sep 2016
- Primary completion
- Sep 2019
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised trial of pd-1 knockout t cells in muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by Peking University. Primary endpoint: Number of participants with Adverse Events and/or Dose Limiting Toxicities at 6 months. Planned start Sep 2016; status: withdrawn.
02
Drugs
pd-1 knockout t cells
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT02863913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02863913.